Noteworthy Thursday Option Activity: AVGO, MRNA, IBM

Moderna (MRNA) saw unusually heavy options activity with 83,430 contracts traded today (≈8.3 million underlying shares), equal to roughly 83.1% of its one‑month average daily share volume (10.0M); the $32 December 19, 2025 call accounted for 17,666 contracts (~1.8M shares). IBM recorded 24,275 option contracts (~2.4M underlying shares), about 69.3% of its one‑month average daily volume (3.5M), led by 5,440 contracts in the $295 put expiring February 20, 2026 (~544k shares). These large option flows indicate significant speculative positioning and could drive near‑term volatility and liquidity changes in both names.

Analysis

Market structure: The sheer magnitude of today’s options flow (MRNA 83,430 contracts ≈8.3M shares ≈83% of ADV; IBM 24,275 contracts ≈2.4M shares ≈69% of ADV) signals concentrated directional positioning rather than routine retail churn. Immediate winners are long MRNA option holders and liquidity providers who will delta-hedge into stocks, putting upward pressure on MRNA spot and futures; losers—if flows are protective puts—are IBM equity holders facing forced selling into downside hedging. The flow tightens supply of available option premium and will steepen IV/skew for the affected strikes over days–weeks, raising cost of capital for volatility sellers in biotech and legacy tech names.

Risk assessment: Tail risks include an adverse FDA decision or negative trial readout for MRNA (high-impact for long-dated calls) and a sudden enterprise-spend shock or IBM earnings miss that validates put-heavy positioning. Time horizons: expect liquidity/IV dislocations in days, directional realization over months (Dec 2025 / Feb 2026 expiries) and fundamental re-pricing over quarters. Hidden dependencies: these blocks could be collars, M&A hedges, or convertible issuance hedges—meaning the visible flow may mask a neutral corporate-structured trade. Key catalysts are upcoming MRNA clinical/FDA timelines, IBM earnings/corporate guidance, and any trade-report filings in the next 1–6 weeks.

Trade implications: For conviction on MRNA upside, prefer capped long-dated exposure (Dec 19, 2025) via vertical call spreads to limit theta; size 0.5–1% portfolio risk per trade and target 2–3x payoff within 6–12 months. For IBM, use limited-risk bearish protection (Feb 20, 2026 $295–$245 bear-put spread) sized 0.5% as a hedge against cyclical IT weakness; consider selling short-dated premium (30–90d) if IV spikes >25% to harvest inflated skew. Consider a small relative-value pair (long MRNA equity or call spread, short IBM equity or put spread) sized 0.5–1% to isolate sector rotation from market beta.

Contrarian angles: Don’t assume directional intent—large blocks often reflect corporate hedges or option-writing by institutions; if IV for MRNA jumps but spot fails to follow within 2–4 weeks, implied volatility collapse will create opportunities to sell premium. The market may be overpricing long-dated convexity: if implied vol falls >30% from peak or MRNA fails to clear the $32 strike in 6–9 months, cut losses early. Historical precedent: concentrated options flows lead to short-term technical moves but frequently mean-revert once delta-hedges are unwound, so prefer limited-risk, asymmetric option structures rather than naked directional size.

Key Decisions for Investors

• Establish a capped bullish position in MRNA: buy Dec 19, 2025 $32–$50 call vertical (or equivalent synthetic) sized to risk 0.5–1.0% of portfolio; target a 2–3x return within 6–12 months, exit/trim if spread loses 50% or implied vol falls >30% from entry.
• Hedge/short IBM asymmetrically: buy Feb 20, 2026 $295–$245 bear-put spread sized to risk 0.5% of portfolio as protection against enterprise-spend shock; take profit if spread doubles or if IBM trades above $335 for a sustained 30-day period.
• Pair trade to isolate sector rotation: allocate a net-neutral 1% position (long MRNA call spread sized 0.5–0.75% vs short IBM equity or buy-to-open put spread 0.5–0.75%) to exploit biotech convexity vs legacy tech cyclicality over the next 6–12 months.
• Volatility premium play: if MRNA IV increases >25% on this flow, sell 30–90 day call spreads (delta ~0.25–0.35) sized to risk 0.5% to capture stretched skew; cut if IV normalizes and position is down 30% or if headline catalysts (FDA/earnings) invalidate the thesis.